Acute Spinal Cord Injury – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 3 PAGES: 46

Acute Spinal Cord Injury - Pipeline Review, H1 2012', provides an overview of the Acute Spinal Cord Injury therapeutic pipeline. This report provides information on the therapeutic development for Acute Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury. 'Acute Spinal Cord Injury - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									    Acute Spinal Cord Injury – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC2013IDB
                                                                                              Publication Date: April 2012




Acute Spinal Cord Injury – Pipeline Review, H1 2012                                           GMDHC2013IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Acute Spinal Cord Injury – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Acute Spinal Cord Injury Overview ..................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Acute Spinal Cord Injury ..................................................................................................... 7
Acute Spinal Cord Injury Therapeutics under Development by Companies ....................................................................................... 9
Acute Spinal Cord Injury Therapeutics under Investigation by Universities/Institutes ...................................................................... 10
Mid Clinical Stage Products.............................................................................................................................................................. 11
    Comparative Analysis .................................................................................................................................................................. 11
Early Clinical Stage Products ........................................................................................................................................................... 12
    Comparative Analysis .................................................................................................................................................................. 12
Pre-Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Acute Spinal Cord Injury Therapeutics – Products under Development by Companies ................................................................... 14
Acute Spinal Cord Injury Therapeutics – Products under Investigation by Universities/Institutes .................................................... 15
Companies Involved in Acute Spinal Cord Injury Therapeutics Development .................................................................................. 16
    Novartis AG ................................................................................................................................................................................. 16
    Acorda Therapeutics, Inc............................................................................................................................................................. 17
    Geron Corporation ....................................................................................................................................................................... 18
    Oxygen Biotherapeutics, Inc. ....................................................................................................................................................... 19
    Asubio Pharmaceuticals, Inc. ...................................................................................................................................................... 20
Acute Spinal Cord Injury – Therapeutics Assessment...................................................................................................................... 21
    Assessment by Monotherapy Products ....................................................................................................................................... 21
    Assessment by Route of Administration ...................................................................................................................................... 22
    Assessment by Molecule Type .................................................................................................................................................... 24
Drug Profiles..................................................................................................................................................................................... 26
    Cethrin - Drug Profile ................................................................................................................................................................... 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    GRNOPC1 - Drug Profile ............................................................................................................................................................. 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    Oxycyte Emulsion - Drug Profile .................................................................................................................................................. 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Chondroitinase Program - Drug Profile ........................................................................................................................................ 31



Acute Spinal Cord Injury – Pipeline Review, H1 2012                                                                                                GMDHC2013IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Acute Spinal Cord Injury – Pipeline Review, H1 2012




         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    ATI355 - Drug Profile ................................................................................................................................................................... 33
         Product Description................................................................................................................................................................. 33
         Mechanism of Action ............................................................................................................................................................... 33
         R&D Progress ......................................................................................................................................................................... 33
    Granulocyte Colony Stimulating Factor - Drug Profile ................................................................................................................. 34
         Product Description................................................................................................................................................................. 34
         Mechanism of Action ............................................................................................................................................................... 34
         R&D Progress ..............................................................................................................................
								
To top